ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

SBTX Skinbiotherapeutics Plc

9.25
0.11 (1.20%)
01 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Skinbiotherapeutics Plc LSE:SBTX London Ordinary Share GB00BF33H870 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.11 1.20% 9.25 9.00 9.50 9.25 9.25 9.25 1,064,455 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Biological Pds,ex Diagnstics 132k -2.84M -0.0163 -5.67 16.1M
Skinbiotherapeutics Plc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker SBTX. The last closing price for Skinbiotherapeutics was 9.14p. Over the last year, Skinbiotherapeutics shares have traded in a share price range of 7.25p to 29.50p.

Skinbiotherapeutics currently has 174,004,323 shares in issue. The market capitalisation of Skinbiotherapeutics is £16.10 million. Skinbiotherapeutics has a price to earnings ratio (PE ratio) of -5.67.

Skinbiotherapeutics Share Discussion Threads

Showing 1101 to 1121 of 23525 messages
Chat Pages: Latest  53  52  51  50  49  48  47  46  45  44  43  42  Older
DateSubjectAuthorDiscuss
05/12/2017
10:32
This bit is useful and the SBTX connection, the IPO:

Since commencing business in August 2016 we have been appointed broker to a number of Companies listed on AIM and have assisted in a number of fundraisings.

Following on from the successful IPO of Saffron Energy plc in February, we have been appointed sole broker to two EIS qualifying IPOs; SkinBio Therapeutics plc and Integumen plc, which are both due to list in early April.

We were appointed Broker to Falanx on 6th June 2017 and W Resources on 14th June respectively.

bobalot
05/12/2017
10:29
Here is some intel about Turner Pope -- looks like a reputable company that has an interest in fledgling medical firms. Perhaps they are looking to buy into SBTX?.

Based near the Bank of England, in the heart of the financial district, Turner Pope Investments (TPI) Ltd is a discretionary management, advisory and execution only stockbroker dealing primarily in exchange listed physical shares on behalf of retail, professional and eligible counterparty clients.

We are focussed on smaller and AIM traded companies, and act as broker, joint broker or placing agent to such corporate clients. Our team has over 200 years of combined experience working in the smaller companies sector.

bobalot
05/12/2017
10:08
Per has just tweeted:Attended the Turner Pope Investments event last night and enjoyed the presentation from CEO Cath O'Neill - SkinBioTherapeutics PLC. Very exciting scientific progress, can only be a success when they go commercial IMHO @SkinBioT
parob
05/12/2017
09:50
Thanks Bob, yes all looking positive here for next year. I am looking to top up and wondered how much time I had before I need to buy.
rafboy
05/12/2017
09:39
It is worth noting that the three development projects are all running concurrently and that will cause the original schedule timeframes to be much earlier than anticipated last April. Take a look at articles and RNS news dating back to August thru to November and a gear change in activity can be noticed.
bobalot
05/12/2017
09:31
Refboy --- well it was originally scheduled for Q3/18 and has now been brought forward to Q2/18. But the creams have now already been formulated and dosage testing has been completed and also the mass manufacturer contracted to make the stuff has completed it's jobs.

Along with the three types of health and safety tests which the cosmetic cream and the basic formulation passed with flying colours.

So, progress has been faster than expected this year already and that might prompt bringing the schedule forward a couple of months. testing will only take a month and if its good then commercialisation will start with a major brand name.

bobalot
05/12/2017
09:24
Here is confirmation for testing the cosmetic cream schedule:

SkinBiotherapeutics readying for cosmetic cream launch after safety test success

SkinBiotix, the company's microbiome platform, will be tested in a cosmteic consumer efficacy study, a far less demanding process than clinical trials.
Around sixty patients will be involved in the study for a month and if successful, it will be allowed on sale almost immediately.

Work on the formulation of the skin cream has also started, O’Neill said, adding this was another crucial part of the product development process.

SkinBiotix recently passed an independent in-vitro (test tube) cytotoxicity safety test with flying colours and now just has two more safety tests to clear before the human efficacy study can begin.

SkinBioTherapeutics presented data recently at a microbiome symposium sponsored by Wellcome Trust that was well received, but the human trial will be a major step forward, she added.

“Once the results [from the human study] are in we are good to go.”
SkinBiotix might be either an ingredient in someone else’s product or a brand in its own right.

www.proactiveinvestors.co.uk/companies/news/186818/skinbiotherapeutics-readying-for-cosmetic-cream-launch-after-safety-test-success-186818.html

bobalot
05/12/2017
09:17
Thanks Bob, I just wondered if the trial timeframe had been brought forward at all.
rafboy
05/12/2017
09:04
Testing for the eczema cream is scheduled for the end of next year and the cosmetic cream will undergo human testing in Q2/18 according to Dr.Cath being quoted in a November article. Thus not 4-5 years away.

So where was the presentation held?, as there has not been any mention of it on the company website or twitter account.

bobalot
05/12/2017
08:41
Interesting development.
rafboy
05/12/2017
08:27
Was there any indication of timings for the cosmetic human trials next year?
rafboy
05/12/2017
08:22
Thanks Deeppockets.
rafboy
05/12/2017
08:02
Intel inside route
trotterstrading
04/12/2017
22:08
Thanks for the update Deeppockets - Prescription cream would be incredible. Currently eczema sufferers only have steroid based creams, which can have devastating side effects, especially during withdrawal. Although, many doctors don’t even consider ‘steroid withdrawsl’ a genuine issue/complaint.

I’m curious, is the cosmetic cream going down a similar ‘intel-inside’ route, or more likely one product under one brand?

loungeact
04/12/2017
20:52
I'm more excited about the Cosmetic cream from a purely investment perspective.
Massive immedisate market.

So not worried about the 3-4 years for the Eczema cream.
That said a shame they can't get something to market sooner for those that do suffer.

onedayrodders
04/12/2017
20:05
Good presentation this evening from Cath. Chairman was also there, he has a great track record in developing life science businesses. Looking good for cosmetic product next year. Anti MRSA product evidence was amazing. Eczema cream 3-4 years away because of regulation. However its aim is to be a prescription cream - massive market! All in track and very impressive!
deeppockets
04/12/2017
17:17
Let's see if you get the message too, mate.
polus
04/12/2017
16:40
It looks like the OPTI MOB have got the message perhaps...discussions about SkinBio most welcome.
bobalot
04/12/2017
14:41
A reasonable request - Polus.
elrico
04/12/2017
14:32
So, my advice, if you're not saying anything NEW..probably best to say nothing and just patiently wait. Take it or leave it.
polus
04/12/2017
14:22
Try looking at all the rubbish the OPTI MOB posted.

A discussion about the latest news would be more interesting.

bobalot
Chat Pages: Latest  53  52  51  50  49  48  47  46  45  44  43  42  Older

Your Recent History

Delayed Upgrade Clock